Zymeworks (ZYME) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 8, 2022 4:22 PM ESTAnnounced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks lead clinical candidate, for total potential payments of up to $1.76 billion, plus royalties on net sales Hosted Early Research and Development day highlighting progress in development of product pipeline and potential applications of proprietary next-generation technology platforms Completed plan to become a Delaware corporation, providing opportunities for enhanced long-term value for securityholders, simplified commercialization efforts and monetization opportunities for product candidates, and greater comparability to peers Reported encouraging preliminary Phase 1 trial results for zanidatamab zovodotin at ESMO Congress, with zanidatamab... More
